Paid clinical trial for Type 1 diabetic patients aged 20-64
We are carrying out a clinical trial in Type 1 diabetic patients to compare the effect of glucose alone and in combination with moxifloxacin (a commonly used antibiotic) on the changes in electrocardiogram (ECG). An ECG is a technique for recording the electrical activity of the heart. This may be useful for preventing ‘Sudden Cardiac Death’ which is more common in diabetic patients compared to healthy people.
This study will be conducted at our clinical trials unit in London Bridge and will involve Type 1 diabetic patients. You will need to attend a screening appointment within 20 days of admission. If successful, you will be required to be in our unit for 1 in-house stay of 5 days / 4 nights and 1 follow-up visit 7-14 days after receiving the last dose of the study drug.
Screening and admission for the trial will be discussed during your telephone screening.
Who can take part?
To be eligible to take part in this study you must fit the following criteria:
- Type 1 diabetic males and females aged between 20 and 64 (inclusive).
- You must weigh at least 48 kg and your Body Mass Index (BMI) within the range 18.0-30.0 kg/m² (inclusive).
- You must be healthy (apart from the confirmed diagnosis Type 1 diabetes) with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk.
- You must not consume tobacco in any form or other nicotine-containing products 3 months before you receive the first study drug administration.
- You must not test positive for hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or alcohol abuse. (Alcohol abuse is defined as a regular weekly intake of more than 14 units).
- You must not have been recently hospitalised due to hypoglycaemia or hyperglycaemia within the past one month.
- You must not consume grapefruit (including juice or extract), Seville oranges, watercress, broccoli, Brussel sprouts, or cabbage 1 week before you are admitted to the study.
- You must be healthy with no underlying medical conditions that may either interfere with participation in the clinical study, and/or put you at any significant risk.
- You must not be on any regular medications, including over the counter medications.
- You must not be pregnant or breastfeeding.
- Female volunteers of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting one menstrual cycle prior to the first day of dosing and continuing until at least 3 months after the last study drug administration.
- Male volunteers must be willing to use appropriate contraception for the treatment period and continuing until at least 3 months after the last study drug administration.
A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.
In recognition of the time involved in taking part in this study, you will receive £940 (£310 bonus and £630 study payment) on completion of the study provided you comply fully with all the study requirements. This amount is based on the anticipated study plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.
Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: firstname.lastname@example.org
Ref: RPL_Nov 2018 (email_website_advert text)
The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.
You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.